Evidence map›Paper›PMID 34664929›Full record

ArticleACS chemical biology2021

Conditional Antisense Oligonucleotides Triggered by miRNA.

Jiahui Zhang, Radhika Sharma, Kitae Ryu, Patrick Shen, Khalid Salaita, Hanjoong Jo

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. miRNA-Based Technologies in Cancer Therapy.Journal of personalized medicine · 2023
    Review
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jiahui ZhangWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30332, United States.ORCID 0000-0002-4949-6217
Radhika SharmaDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Kitae RyuWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30332, United States.
Patrick ShenDepartment of Chemistry, Emory University, Atlanta, Georgia 30322, United States.
Khalid SalaitaWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30332, United States.ORCID 0000-0003-4138-3477
Hanjoong JoWallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia 30332, United States.ORCID 0000-0003-1833-372X
Georgia Institute of Technology · USEmory University · US

Funding

T cell triggering events and hypertensionP01HL095070 · NHLBI · EMORY UNIVERSITY · PI JO, HANJOONG · 2009 to 2019
$20.5M
Shear stress, endothelial miRNAs, and AV calcificationR01HL119798 · NHLBI · EMORY UNIVERSITY · PI JO, HANJOONG, YOGANATHAN, AJIT P · 2013 to 2022
$4.7M
HEG1 in endothelial function and atherosclerosisR01HL158571 · NHLBI · EMORY UNIVERSITY · PI JO, HANJOONG · 2021 to 2024
$2.7M
Catalytic Nanotherapies to Treat Lung DiseaseR01HL142866 · NHLBI · EMORY UNIVERSITY · PI SALAITA, KHALID S., WONGTRAKOOL, CHERRY P · 2018 to 2021
$1.7M
Role of flow-sensitive KLK10 in endothelial dysfunction and atherosclerosisR01HL139757 · NHLBI · EMORY UNIVERSITY · PI JO, HANJOONG · 2018 to 2021
$1.6M
NHLBI NIH HHS P01 HL095070NHLBI NIH HHS R01 HL119798NHLBI NIH HHS R01 HL139757NHLBI NIH HHS R01 HL142866NHLBI NIH HHS R01 HL158571
6 · The paper itself

Abstract

Antisense oligonucleotides (ASOs) are single-stranded short nucleic acids that silence the expression of target mRNAs and show increasing therapeutic potential. Since ASOs are internalized by many cell types, both normal and diseased cells, gene silencing in unwanted cells is a significant challenge for their therapeutic use. To address this challenge, we created conditional ASOs that become active only upon detecting transcripts unique to the target cell. As a proof-of-concept, we modified an HIF1α ASO (EZN2968) to generate miRNA-specific conditional ASOs, which can inhibit HIF1α in the presence of a hepatocyte-specific miRNA, miR-122, via a toehold exchange reaction. We characterized a library of nucleic acids, testing how the conformation, thermostability, and chemical composition of the conditional ASO impact the specificity and efficacy in response to miR-122 as a trigger signal. Optimally designed conditional ASOs demonstrated knockdown of HIF1α in cells transfected with exogenous miR-122 and in hepatocytes expressing endogenous miR-122. We confirmed that conditional ASO activity was mediated by toehold exchange between miR-122 and the conditional ASO duplex, and the magnitude of the knockdown depended on the toehold length and miR-122 levels. Using the same concept, we further generated another conditional ASO that can be triggered by miR-21. Our results suggest that conditional ASOs can be custom-designed with any miRNA to control ASO activation in targeted cells while reducing unwanted effects in nontargeted cells.

Indexed as

Cell Line, TumorDose-Response Relationship, DrugDrug Delivery SystemsGene Expression RegulationGene Knockdown TechniquesHepatocytesHumansHypoxia-Inducible Factor 1, alpha SubunitMicroRNAsMolecular MimicryOligonucleotides, AntisenseOptical ImagingTime FactorsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMicroRNAsMIRN122 microRNA, humanOligonucleotides, Antisense

Identifiers

PMID34664929
PMCPMC10982875
OpenAlexW3205075144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.